EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease

Armelle Pindon iD, Nicola Brunetti-Pierri iD, Kathy H Young iD, Mary K Young iD, Maria J Macias iD, Xiulei Mo iD

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025

DOI: 10.1002/ajmg.c.32156 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2025. Verfasst von Armelle Pindon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Myhre Syndrome Foundation, Richardson, Texas, USA. Hauptthemen laut MEDLINE: Drug Discovery, Smad4 Protein, Cryptorchidism, Hand Deformities, Congenital. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Agència de Gestió d'Ajuts Universitaris i de Recerca, PDC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myhre syndrome is a rare, multisystemic disorder caused by gain‐of‐function mutations in the SMAD4 gene, a key component of the TGF‐β signaling pathway. These mutations lead to manifestations affecting neurodevelopment, bone and joint development, fibrosis and stenosis, immune responses, reproductive health, and cardiac function. The Myhre Syndrome Foundation (MSF) is a patient‐centered organization focused on accelerating drug discovery while supporting patients, prioritizing research targeting fibrosis/stenosis and autism/intellectual and developmental disabilities, the most significant burdens reported by patients. Their short‐term strategy involves: (1) Creating and running a preclinical platform to screen potential treatments using patient‐derived and animal models. (2) Clinical readiness, addressing challenges associated with low disease incidence and heterogeneity in clinical trial design, by developing multi‐domain endpoints, responder index, and biobanks/biomarkers. (3) Target identification investigating SMAD4 pathogenic variants rewiring protein–protein interactions in key signaling pathways. (4) Fostering partnerships with regulatory authorities, industries, and other patient research organizations. The MSF portfolio includes targeting fibrosis with immunotherapy using FAP‐CAR‐T cells, and a precision medicine approach aimed at restoring normal SMAD4 function through gene editing and small molecules. MSF aims to develop therapies that address both acute and chronic manifestations of this complex disease, improving the quality of life for affected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoverySmad4 ProteinCryptorchidismHand Deformities, CongenitalIntellectual DisabilityRare DiseasesGrowth DisordersHumansAnimalsFaciesSignal Transduction

Stichwörter der Autor:innen

Myhre syndromeSMAD4TGF‐βdrug discoverymultisystemicneo‐PPIpatient‐organization

Substanzen

Smad4 ProteinSMAD4 protein, human

Autor:innen und Institutionen

  • Myhre Syndrome Foundation, Richardson, Texas, USA.
  • Department of Translational Medicine, Federico II University, Naples, Italy.
  • Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
  • Genomics and Experimental Medicine Program, Scuola Superiore Meridionale (SSM, School of Advanced Studies), Naples, Italy.
  • Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology (BIST), Baldiri Reixac, Barcelona, Spain.
  • ICREA, Barcelona, Spain.

ORCID-Profile: Armelle Pindon, Nicola Brunetti-Pierri, Kathy H Young, Mary K Young, Maria J Macias, Xiulei Mo

Förderung

  • NCATS NIH HHS
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • PDC
  • EU-OPENSCREEN Transformation and Resilience Plan
  • Knowledge Industry Program Product 2023
  • EU-OPENSCREEN MedChem
  • NCI NIH HHS
  • EU-OPENSCREEN-DRIVE

Zitieren

APA

Pindon, A., Brunetti-Pierri, N., Young, K. H., Young, M. K., Macias, M. J., & Mo, X. (2025). Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.32156

Vancouver

Pindon A, Brunetti-Pierri N, Young KH, Young MK, Macias MJ, Mo X. Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025. doi:10.1002/ajmg.c.32156

BibTeX
@article{Pindon2025,
  author = {Pindon, Armelle and Brunetti-Pierri, Nicola and Young, Kathy H and Young, Mary K and Macias, Maria J and Mo, Xiulei},
  title = {Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2025},
  doi = {10.1002/ajmg.c.32156}
}
Kostenlos starten →